Psoriasis Clinical Trials

Currently Enrolling

UCB Protocol PS0007: A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (CIMcare) (Clinical Trial Conducted in Phoenix, Arizona – 7th Street Location) | Learn More » | Request to Join This Study »

Corrona Psoriasis Registry (Phoenix, AZ): A study of the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologists. Any adult patient who has started a biologic therapy in the past year, or is being prescribed a biologic therapy by one of our dermatologists, is eligible! (Clinical Trial Conducted in Phoenix, Arizona – 7th Street Location) | Learn More »

Corrona Protocol PSO-500: A Phase 4 study of the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologists. Compares systemic psoriasis therapies that are available for prescription. (Clinical Trial Conducted in Rockville, Maryland) | Learn More » | Request to Join This Study »

Abbvie Protocol M19-164: A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Have a Suboptimal Response to Secukinumab or Ixekizumab and Are Switched to Risankizumab. (Clinical Trial Conducted in Rockville, Maryland) | Learn More » | Request to Join This Study »

Corrona Psoriasis Registry (Rockville, MD): Any adult patient who started a biologic therapy in the past year, or is being prescribed a biologic therapy, is eligible! Patients come to the Rockville office every 6 months for 8 years will receive a $25 gift card. (Clinical Trial Conducted in Rockville, Maryland) | Learn More » | Request to Join This Study »

ESPRIT Chronic Plaque Psoriasis Registry: A 10-year registry of patients taking HUMIRA® for Psoriasis. Patients who volunteer to participate will be asked to provide information about their medical history and experiences with HUMIRA®. No registry-specific testing will be performed. Patients will be asked to provide data on their experiences with HUMIRA® approximately every 6 months, or as determined by the study doctor. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry. (Clinical Trial Conducted in Rockville, Maryland) | Learn More » | No Longer Enrolling

Celgene Protocol 826652: A Phase 4, open-label study of the effects of apremilast on vascular inflammation and cardiometabolic function in psoriasis. For adult patients with moderate to severe plaque psoriasis. (Clinical Trial Conducted in Rockville, Maryland) | Learn More » | No Longer Enrolling

Lilly Protocol I6T-MC-AMAH: A Phase 3, multicenter, long-term extension to evaluate the long-term safety and maintenance of treatment effect of LY3074828 (il-23 inhibitor) in patients with moderate-to-severe plaque psoriasis who have previously completed participation in I6T-MC-AMAH. (Clinical Trial Conducted in Rockville, Maryland) | Learn More » | No Longer Enrolling